Polybatics closer to commercialising ‘magic bullet’

Last updated 11:07 24/11/2009

Relevant offers


Expedia's New Zealand boss speaks out on competition fears, tax structure Porirua cbd gets two fibre networks and high-speed wi-fi Former casino magnate and vineyard owner sued for $3.5 million Ferrybank design finalists to go on display at Waikato Museum Architecturally-designed Wellington central building up for sale How Toyota used Nascar to sway loyal US car buyers VW announces cleaning solution for dirty diesels AFT Pharmaceuticals to list on NZX and ASX in December Brokers view: Positivity may be returning for Kathmandu Successful New Zealanders celebrated at Moet event

Polybatics, a biotech start-up, is edging closer to commercializing a process for delivering custom payloads into living cells, potentially giving medical specialists a nanotechnology weapon to target disease.

The Palmerston North-based company, perched in a business park alongside Massey University, designs and manufactures natural bionanoparticles. These 'biobeads,' as they are known, can carry a range of proteins including antibodies, enzymes and antigens into living tissue. 

Massey University Professor of Microbiology Bernd Rehm developed the technology which uses a natural polymer granule produced by bacteria under stress. Polybatics was set up to commercialise the research, gaining a $1 million grant this year and with plans to seek a further tranche in 2010.

The company now needs to demonstrate that biobeads can be scaled up from its laboratory proof-of-concept. 

One demonstration was attaching tuberculosis antigens to the biobeads and eliciting a response against the disease in mice. Applications of the biobeads and attached functional proteins include bioseparations, antibody production and purification, diagnostics, antigen delivery, biocatalysts and drug delivery, said managing director Tracy Thompson. 

Polybatics has one global patent and three pending. The company has four secondees from Massey and Canterbury universities. They will become full-time employees and receive stock options "when the time is appropriate," said Thompson. 

"It's not quite time for them to quit their university jobs," he said. 


Ad Feedback
Special offers

Featured Promotions

Sponsored Content